A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension

被引：3

作者：

Fernández-Vega F. ^{[1
]}

Abellan J. ^{[1
]}

Sanz De Castro S. ^{[1
]}

Cucalón J.M. ^{[1
]}

Maceira B. ^{[1
]}

Gómez De La Cámara A. ^{[1
]}

机构：

[1] Servicio de Nefrologia, Unidad de Hipertension, Hospital Central de Asturias, Oviedo

来源：

International Urology and Nephrology | 2001年 / 32卷 / 4期

关键词：

Elderly; Hypertension; Kidney function; Losartan;

D O I：

10.1023/A:1014443020307

中图分类号：

学科分类号：

摘要：

Despite progress in the detection and treatment of hypertension the percentage of patients with controlled hypertension has failed to increase. The problem of poor blood pressure control is even more serious in elderly hypertensives than in the rest of the population. The antihypertensive drugs of the AIIRA (non-peptide angiotension II receptor antagonist) class are drugs whose use and experience are increasing and whose properties make them particularly useful in the elderly. We tried to assess the efficacy of treatment with losartan, the first AIIRA drug in a cohort of elderly patients with essential hypertension and to assess the percentage of patients achieving optimum BP control and to evaluate its safety, tolerability and metabolic effects. The intervention proved to be highly effective, achieving the anticipated blood pressure levels in the elderly in 77% of subjects after a 16-week follow-up, with very good tolerability. Renal function remained unchanged, as did the subjects' lipid profile.

引用

页码：519 / 523

页数：4

共 15 条

[1]

WHO - International Society of Hypertension guidelines for the management of hypertension, J Hypertens, 17, pp. 151-183, (1999)

[2]

Control de la Hipertensión Arterial en España. Ministerio de Sanidad y Consumo. Sociedad-Liga Española para la Lucha Contra la Hipertensión Arterial, (1996)

[3]

Coca A., Evolución del control de la hipertensión arterial en España. Resultados del Estudio Controlpress 98, Hipertensión, 8, pp. 298-307, (1998)

[4]

Banegas J.R., Rodriguez-Artalejo F., De La Cruz Troca J.J., Guallar-Castrillon P., Del Rey Calero J., Blood pressure in Spain. Distribution, awareness, control and benefits of a reduction in average pressure, Hypertension, 32, pp. 998-1002, (1998)

[5]

Lenfant C., Rocella E.J., A call to action for more aggressive treatment of hypertension, J Hypertension, 17, pp. S3-S7, (1999)

[6]

Burrell L.M., Johnston C.I., Angiotensin II receptor antagonists: Potential in elderly patients with cardiovascular disease, Drugs-Aging, 10, pp. 421-434, (1997)

[7]

The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of losartan in the elderly study, Drugs-Aging, 12, pp. 423-428, (1998)

[8]

MacMahon S., Et al., Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias, Lancet, 335, pp. 765-774, (1990)

[9]

Collins R., Et al., Blood pressure, stroke and coronary heart disease, Part 2: Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context, Lancet, 335, pp. 827-838, (1990)

[10]

The 6th report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC VI), Arch Intern Med, 157, pp. 2413-2446, (1997)

← 1 2 →